Anti-cancer drug discovery and development bcl-2 family small molecule inhibitors

Qiang Liu, Hong-Gang Wang

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Deregulated apoptosis is a hallmark of cancer, and the B-cell lymphoma-2 (Bcl-2) family of proteins is pivotal to mediating the intrinsic pathway of this process. Recent advances have yielded both pan-Bcl-2 small molecule inhibitors (SMIs) that inhibit both the Bcl-2 and the Mcl-1 arm of the Bcl-2 family antiapoptotic proteins, as well as selective SMIs to differentially target the two arms. Of these SMIs, ABT-263 (navitoclax), AT-101 [(-)-gossypol], and obatoclax (GX15-070) are currently in clinical trials for multiple cancers. While pan-Bcl-2 inhibitors such as AT-101 and obatoclax can be more toxic for inhibiting all members of the anti-apoptotic Bcl-2 family of proteins, resistance can quickly develop for ABT-263, a selective Bcl-2 inhibitor. In this article, we discuss the current status of Bcl-2 family SMIs in preclinical and clinical development. As Mcl-1 upregulation is a major mechanism of ABT-263 resistance, Mcl-1-specific inhibitors are expected to be efficacious both in combination/sequential treatments and as a single agent against cancers resistant to ABT-263.

Original languageEnglish (US)
Pages (from-to)557-565
Number of pages9
JournalCommunicative and Integrative Biology
Volume5
Issue number6
DOIs
StatePublished - Nov 1 2012

Fingerprint

antineoplastic agents
B-Cell Lymphoma
Drug Discovery
lymphoma
B-lymphocytes
Neoplasms
neoplasms
Gossypol
gossypol
Proteins
Poisons
clinical trials
Up-Regulation
apoptosis
proteins
navitoclax
Clinical Trials
Apoptosis

All Science Journal Classification (ASJC) codes

  • Agricultural and Biological Sciences(all)

Cite this

@article{4f2e77a2d278488a8bb848ee3e9fb1ff,
title = "Anti-cancer drug discovery and development bcl-2 family small molecule inhibitors",
abstract = "Deregulated apoptosis is a hallmark of cancer, and the B-cell lymphoma-2 (Bcl-2) family of proteins is pivotal to mediating the intrinsic pathway of this process. Recent advances have yielded both pan-Bcl-2 small molecule inhibitors (SMIs) that inhibit both the Bcl-2 and the Mcl-1 arm of the Bcl-2 family antiapoptotic proteins, as well as selective SMIs to differentially target the two arms. Of these SMIs, ABT-263 (navitoclax), AT-101 [(-)-gossypol], and obatoclax (GX15-070) are currently in clinical trials for multiple cancers. While pan-Bcl-2 inhibitors such as AT-101 and obatoclax can be more toxic for inhibiting all members of the anti-apoptotic Bcl-2 family of proteins, resistance can quickly develop for ABT-263, a selective Bcl-2 inhibitor. In this article, we discuss the current status of Bcl-2 family SMIs in preclinical and clinical development. As Mcl-1 upregulation is a major mechanism of ABT-263 resistance, Mcl-1-specific inhibitors are expected to be efficacious both in combination/sequential treatments and as a single agent against cancers resistant to ABT-263.",
author = "Qiang Liu and Hong-Gang Wang",
year = "2012",
month = "11",
day = "1",
doi = "10.4161/cib.21554",
language = "English (US)",
volume = "5",
pages = "557--565",
journal = "Communicative and Integrative Biology",
issn = "1942-0889",
publisher = "Landes Bioscience",
number = "6",

}

Anti-cancer drug discovery and development bcl-2 family small molecule inhibitors. / Liu, Qiang; Wang, Hong-Gang.

In: Communicative and Integrative Biology, Vol. 5, No. 6, 01.11.2012, p. 557-565.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-cancer drug discovery and development bcl-2 family small molecule inhibitors

AU - Liu, Qiang

AU - Wang, Hong-Gang

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Deregulated apoptosis is a hallmark of cancer, and the B-cell lymphoma-2 (Bcl-2) family of proteins is pivotal to mediating the intrinsic pathway of this process. Recent advances have yielded both pan-Bcl-2 small molecule inhibitors (SMIs) that inhibit both the Bcl-2 and the Mcl-1 arm of the Bcl-2 family antiapoptotic proteins, as well as selective SMIs to differentially target the two arms. Of these SMIs, ABT-263 (navitoclax), AT-101 [(-)-gossypol], and obatoclax (GX15-070) are currently in clinical trials for multiple cancers. While pan-Bcl-2 inhibitors such as AT-101 and obatoclax can be more toxic for inhibiting all members of the anti-apoptotic Bcl-2 family of proteins, resistance can quickly develop for ABT-263, a selective Bcl-2 inhibitor. In this article, we discuss the current status of Bcl-2 family SMIs in preclinical and clinical development. As Mcl-1 upregulation is a major mechanism of ABT-263 resistance, Mcl-1-specific inhibitors are expected to be efficacious both in combination/sequential treatments and as a single agent against cancers resistant to ABT-263.

AB - Deregulated apoptosis is a hallmark of cancer, and the B-cell lymphoma-2 (Bcl-2) family of proteins is pivotal to mediating the intrinsic pathway of this process. Recent advances have yielded both pan-Bcl-2 small molecule inhibitors (SMIs) that inhibit both the Bcl-2 and the Mcl-1 arm of the Bcl-2 family antiapoptotic proteins, as well as selective SMIs to differentially target the two arms. Of these SMIs, ABT-263 (navitoclax), AT-101 [(-)-gossypol], and obatoclax (GX15-070) are currently in clinical trials for multiple cancers. While pan-Bcl-2 inhibitors such as AT-101 and obatoclax can be more toxic for inhibiting all members of the anti-apoptotic Bcl-2 family of proteins, resistance can quickly develop for ABT-263, a selective Bcl-2 inhibitor. In this article, we discuss the current status of Bcl-2 family SMIs in preclinical and clinical development. As Mcl-1 upregulation is a major mechanism of ABT-263 resistance, Mcl-1-specific inhibitors are expected to be efficacious both in combination/sequential treatments and as a single agent against cancers resistant to ABT-263.

UR - http://www.scopus.com/inward/record.url?scp=84869748202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869748202&partnerID=8YFLogxK

U2 - 10.4161/cib.21554

DO - 10.4161/cib.21554

M3 - Article

VL - 5

SP - 557

EP - 565

JO - Communicative and Integrative Biology

JF - Communicative and Integrative Biology

SN - 1942-0889

IS - 6

ER -